OPSUMIT® is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1). PAH is high blood pressure in the arteries of your lungs. OPSUMIT® can:
Women who are able to get pregnant must have negative pregnancy tests:
Improvement was measured by the 6-minute walk distance (6MWD), a test that measures the distance you can walk in 6 minutes. It is one test that your doctor may perform to assess your condition.
More patients taking OPSUMIT® saw an improvement of at least one functional class. At Month 6 in the clinical trial, 22% of patients taking OPSUMIT® improved their functional class compared with 13% of patients not taking it.
Functional class is a common way for doctors to assess the seriousness of your PAH, which can help them with making treatment decisions. The higher the functional class, the more severe the disease. Improved functional class means you can do more physical activity with fewer limitations. It does not always mean symptom improvement. According to PAH experts, maintaining or improving functional class is often an important goal of PAH treatment. Talk to your doctor to discuss your own treatment goals.
Patients taking OPSUMIT® were 45% less likely to have their PAH progress than patients not taking it.*
*In the clinical trial, disease progression included the need for injectable PAH medication or other worsening of PAH (decreased 6MWD, PAH symptoms getting worse, and the need for new PAH treatment). Overall, 31.4% of patients who took OPSUMIT® and 46.4% of patients who did not take OPSUMIT® had their PAH progress. On average, patients took OPSUMIT® for 2 years.
In the clinical trial, 20.7% of patients who took OPSUMIT® and 33.6% of patients who did not take OPSUMIT® were hospitalized for PAH. On average, patients took OPSUMIT® for 2 years.
Improvement was measured by the 6-minute walk distance (6MWD), a test that measures the distance you can walk in 6 minutes. It is one test that your doctor may perform to assess your condition.
More patients taking OPSUMIT® saw an improvement of at least one functional class. At Month 6 in the clinical trial, 22% of patients taking OPSUMIT® improved their functional class compared with 13% of patients not taking it.
Functional class is a common way for doctors to assess the seriousness of your PAH, which can help them with making treatment decisions. The higher the functional class, the more severe the disease. Improved functional class means you can do more physical activity with fewer limitations. It does not always mean symptom improvement. According to PAH experts, maintaining or improving functional class is often an important goal of PAH treatment. Talk to your doctor to discuss your own treatment goals.
Patients taking OPSUMIT® were 45% less likely to have their PAH progress than patients not taking it.*
*In the clinical trial, disease progression included the need for injectable PAH medication or other worsening of PAH (decreased 6MWD, PAH symptoms getting worse, and the need for new PAH treatment). Overall, 31.4% of patients who took OPSUMIT® and 46.4% of patients who did not take OPSUMIT® had their PAH progress. On average, patients took OPSUMIT® for 2 years.
In the clinical trial, 20.7% of patients who took OPSUMIT® and 33.6% of patients who did not take OPSUMIT® were hospitalized for PAH. On average, patients took OPSUMIT® for 2 years.
You are being directed to a third-party website.
This link is provided for your convenience. Please note that this third-party website is not controlled by OPSUMIT® or subject to our privacy policy.
Thank you for visiting our site. We hope your visit was informative
About Cheryl: Cheryl was diagnosed with PAH in 2011. She is a mother, grandmother, and photographer who loves exploring the outdoors. Cheryl is focused on looking forward, setting goals with her doctor, and knowing when to "sit out" and rest.
About Karla: Karla was diagnosed with PAH in 2003. She finds the greatest joy in spending time with family and loves anything that involves the theater. Karla knows the importance of setting goals with her "new normal" in mind.